Liquidia Corporation (LQDA)
Health Care ยท Pharmaceutical Preparations
Liquidia Corporation (LQDA) is listed on Nasdaq, where its shares have traded since July 26, 2018. SentiSense covers Liquidia Corporation in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations. Roger Jeffs is its chief executive officer. The company reports 216 employees, and its corporate website is www.liquidia.com.
About Liquidia Corporation
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Latest reported results
Liquidia Corporation reported revenue of $171.7 million for Q2 FY2026, up 1842.7% from the same period a year earlier.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 325 institutions reported holding LQDA, with 72.5 million shares worth $5.8 billion in aggregate. The largest reported holders were BlackRock, Farallon Capital Management and Caligan Partners. Of the 5 largest reported holders, 2 added shares, 1 reduced its position and 2 held their positions unchanged during the quarter.
More on LQDA
- LQDA sentiment: whether news and social coverage of Liquidia Corporation leans bullish or bearish, and the stories driving it.
- LQDA ownership: all 325 reporting institutions, plus insider and congressional trades.
- LQDA financials: revenue, net income, operating margin and free cash flow through Q2 FY2026.
Frequently asked questions
What does Liquidia Corporation do?
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease.
What sector is LQDA in?
SentiSense classifies Liquidia Corporation in the Health Care sector, and its Standard Industrial Classification is Pharmaceutical Preparations.
Where does LQDA stock trade?
Liquidia Corporation (LQDA) is listed on Nasdaq, where its shares have traded since July 26, 2018.
Who is the CEO of Liquidia Corporation?
Roger Jeffs is the chief executive officer of Liquidia Corporation.